Clinical Competition Candidate
AMITIZA
AMITIZA carries product patent, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 16 months away. Active clinical competition may compress the generic entry window.
LOE window
16months
to latest listed patent expiry (October 25, 2027)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (listed)
Use-code patent (none)
Patent count: 3
Complexity score: 1/5
Clinical competition
Score: 5/5
Active trials linked: 57
Phase 2/3 trials: 28
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: LUBIPROSTONE
Applicant (NDA holder): SUCAMPO PHARMA AMERICAS LLC
Confidence: High